<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161134</url>
  </required_header>
  <id_info>
    <org_study_id>P1CX04001</org_study_id>
    <nct_id>NCT01161134</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition</brief_title>
  <official_title>Comparative Bioavailability Study of Meloxicam 15 mg Tablets (Dr. Reddy's Laboratories Ltd., Generics) Vs. Mobic® 15 mg Tablets (Boehringer Ingelheim Pharmaceuticals Inc.,Usa) in Healthy Male And/Or Female Volunteers Under Fasting Conditions-P1cx04001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the relative bioavailability of one 15 mg&#xD;
      Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam)&#xD;
      Tablet (Boehringer Ingelheim Pharmaceuticals Inc., USA) under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty eight (twenty six study subjects + two alternate subjects)healthy male and/or female&#xD;
      subjects participated in an open label, two-period, two-sequence, two- treatment,single dose,&#xD;
      two-way crossover study with at least 14 days washout between doses conducted under fasting&#xD;
      conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence on Cmax and AUC parameters</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Meloxicam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mobic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam</intervention_name>
    <description>Meloxicam Tablets 15 mg</description>
    <arm_group_label>Meloxicam</arm_group_label>
    <arm_group_label>Mobic</arm_group_label>
    <other_name>Mobic Tablets 15 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject must be a healthy male or female volunteer.If the volunteer is female. she&#xD;
             must demonstrate β-CG levels consistent with the nongravid state at the medical&#xD;
             screening visit and at check-in for Period 1 and agree to remain abstinent or use&#xD;
             double-barrier contraception (partner using condom and female volunteer using&#xD;
             diaphragm, contraceptive sponge, spermicide, or IUD). If the female is post-menopausal&#xD;
             or is surgically sterile, she is exempt from this requirement. (Postmenopausal is&#xD;
             defined as no menses for the previous 1 year. If cessation of menses is within 18&#xD;
             months, FSH and/or LH must be documented prestudy as elevated into the postmenopausal&#xD;
             range.).&#xD;
&#xD;
          2. The subject must be between the ages of 18 - 55 years old (inclusive).&#xD;
&#xD;
          3. The Subject's body mass index (BMI) must be within 19.0 - 30.0 (Kg/m2).&#xD;
&#xD;
          4. The subject must be a non-smoker and not using any nicotine products.&#xD;
&#xD;
          5. The subject must sign the written consent form (Research Subject Information and&#xD;
             Consent Form) prior to study entry.&#xD;
&#xD;
          6. The subject must have clinically acceptable results from the screening procedure&#xD;
             including blood pressure, heart rate, ECG, physical exam, medical history, hematology,&#xD;
             biochemistry, urinalysis. and infection screen (Hepatitis B Antigen, Hepatitis C&#xD;
             Antibody, HIV)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a history of clinically significant gastro-intestinal, dermatological,&#xD;
             cardiovascular, renal, hematological, neurological, hepatic, pulmonary, or endocrine&#xD;
             disease in the last 12 months.&#xD;
&#xD;
          2. Subjects determined by the Investigator to have any medical condition which may affect&#xD;
             the absorption, distribution, metabolism or excretion of the investigational product,&#xD;
             or that could jeopardize their health or prejudice the results (e.g. history of&#xD;
             surgery of the gastro-intestinal tract, except for appendectomy).&#xD;
&#xD;
          3. Subjects with a known allergy to meloxicam (Mobic) or other nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDS) [e.g. Motrin® (ibuprofen), Celebrex® (celecoxib).&#xD;
             Vioxx® (rofecoxib). Naprelan® and Anaprox®, (naproxen sodium), Lodine® (etodolac),&#xD;
             Cataflam® (diclofenac potassium). Voltaren® and Arthrotec®(diclofenac sodium), etc.].&#xD;
&#xD;
          4. Females who are pregnant, breastfeeding, or are likely to become pregnant.&#xD;
&#xD;
          5. Subjects with any clinically significant illness within four weeks prior to Period 1&#xD;
             dosing.&#xD;
&#xD;
          6. Subjects with a positive saliva alcohol test at check-in for any period.&#xD;
&#xD;
          7. Subjects with a history of alcohol, drug or substance abuse in the past 12 months.&#xD;
&#xD;
          8. Subjects who have used any prescription medication within 14 days of Period 1 dosing&#xD;
             or over-the-counter medication within 14 days of Period 1 dosing.&#xD;
&#xD;
          9. Subjects deemed uncooperative or noncompliant.&#xD;
&#xD;
         10. Subjects who have consumed alcohol within 48 hours prior to Period 1 and Period 2&#xD;
             dosing.&#xD;
&#xD;
         11. Subjects who have consumed xanthine-containing products (including caffeine,&#xD;
             theobromines, etc.) within 48 hours prior to Period 1 dosing.&#xD;
&#xD;
         12. Subjects who have consumed food or beverages containing grapefruit (e.g. fresh,&#xD;
             Canned, or frozen) within 14 days prior to the administration of the study medication.&#xD;
&#xD;
         13. Subjects who have had an abnormal diet within 30 days prior to Period 1 dosing.&#xD;
&#xD;
         14. Subjects who have participated in an investigational drug study or who have donated&#xD;
             more than 100 mL of blood within 30 days prior to Period 1 dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepen M Patel, M.D., C.C.F.P.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allied Research International Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allied Research International Inc.</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2004</verification_date>
  <study_first_submitted>July 12, 2010</study_first_submitted>
  <study_first_submitted_qc>July 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2010</study_first_posted>
  <last_update_submitted>July 12, 2010</last_update_submitted>
  <last_update_submitted_qc>July 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Group leader-Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

